Compare ACU & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACU | VRCA |
|---|---|---|
| Founded | 1867 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 160.6M | 137.3M |
| IPO Year | 1994 | 2018 |
| Metric | ACU | VRCA |
|---|---|---|
| Price | $48.94 | $6.84 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $50.00 | $17.00 |
| AVG Volume (30 Days) | 11.0K | ★ 32.2K |
| Earning Date | 04-23-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.56% | N/A |
| EPS Growth | ★ 1.63 | N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $196,541,816.00 | $35,577,000.00 |
| Revenue This Year | $5.67 | N/A |
| Revenue Next Year | $5.25 | $94.44 |
| P/E Ratio | $198.17 | ★ N/A |
| Revenue Growth | 1.05 | ★ 370.22 |
| 52 Week Low | $35.50 | $0.53 |
| 52 Week High | $47.56 | $9.82 |
| Indicator | ACU | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 74.41 | 61.70 |
| Support Level | $40.57 | $5.32 |
| Resistance Level | N/A | $8.19 |
| Average True Range (ATR) | 1.58 | 0.53 |
| MACD | 0.40 | 0.09 |
| Stochastic Oscillator | 86.58 | 82.95 |
Acme United Corp is a supplier of first aid and medical products and cutting technology to the school, home, office, hardware, sporting goods, and industrial markets. Its principal products sold across all segments are first aid kits and medical products, scissors, shears, knives, rulers, pencil sharpeners, and sharpening tools. The Company sells its products to mass market and e-commerce retailers, industrial distributors, wholesale, contract, and retail stationery distributors, office supply superstores, sporting goods stores, and hardware chains. The Company's reportable business segments consist of the United States, Canada, and Europe, out of which the majority of the company's revenue is derived from the United States.
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.